Randomized controlled study of a novel triple nitazoxanide (NTZ) ‐containing therapeutic regimen versus the traditional regimen for eradication of Helicobacter pylori infection

ConclusionNitazoxanide‐containing triple therapy is a promising therapy for the first‐line eradication of H. pylori. (ClinicalTrials.gov Identifier: NCT02422706).

Source: Helicobacter - May 19, 2017 Category: Gastroenterology Authors: Mona AH Shehata, Raghda Talaat, Samah Soliman, Huda Elmesseri, Shaimaa Soliman, Sherief Abd ‐Elsalam Tags: ORIGINAL ARTICLE Source Type: research